TSS
GYRE icon

Two Sigma Securities’s Gyre Therapeutics GYRE Stock Holding History

Two Sigma Securities’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,336
Closed -$9.66K – 3243
2023
Q3 		$9.66K Buy
+1,336
New +$8.95K ﹤0.01% 2699
2023
Q2 		– Sell
-3,383
Closed -$10.5K – 3009
2023
Q1 		$10.5K Sell
3,383
-1,921
-36% -$7.3K ﹤0.01% 2448
2022
Q4 		$21K Buy
5,304
+3,489
+192% +$14.2K ﹤0.01% 2270
2022
Q3 		$7K Buy
+1,815
New +$23K ﹤0.01% 2445
2017
Q3 		– Sell
-1,586
Closed -$55K – 1038
2017
Q2 		$55K Buy
+1,586
New +$56.9K 0.01% 714
2017
Q1 		– Sell
-200
Closed -$15K – 984
2016
Q4 		$15K Buy
+200
New +$18K 0.01% 666

Other funds holding GYRE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Parallax Volatility Advisers
Parallax Volatility Advisers San Francisco, California $38.6B AUM 45.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Two Sigma Securities's GYRE Position: Q4 2023 in Review

Two Sigma Securities sold out of Gyre Therapeutics (GYRE) in Q4 2023, closing a stake of 1,336 shares — an estimated $9.66K sold.

Two Sigma Securities first reported a position in GYRE in Q4 2016 and held it in 6 quarters. The position peaked at $55K in Q2 2017. 16 funds tracked by Wall St. Rank hold GYRE as of Q4 2023.

  • Two Sigma Securities reported no remaining Gyre Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Two Sigma Securities sold 1,336 Gyre Therapeutics shares in Q4 2023, an estimated $9.66K.
  • Two Sigma Securities first reported a position in Gyre Therapeutics in Q4 2016 and held it in 6 quarters.
  • Two Sigma Securities's Gyre Therapeutics position peaked at $55K in Q2 2017.
  • 16 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q4 2023.

Based on Two Sigma Securities's 13F filing for Q4 2023, filed 14 Feb 2024.